Global Innovative Platforms GIPL
OTC GIPL
$0.50 +0.00 (+0.00%)
At close: Oct 19, 2026 · 4:00 PM EDT

Global Innovative Platforms (GIPL) EBITDA Margin (2025 - 2026)

Updated

Global Innovative Platforms (GIPL) recorded EBITDA Margin of -453.17% in fiscal Q3 2026 (quarter ended Jun 30, 2026), down 323.38 percentage points from the prior quarter.

Analysis

Global Innovative Platforms (GIPL) EBITDA Margin (2025 - 2026) Analysis & Trends

On a TTM basis, Global Innovative Platforms' EBITDA Margin came in at -333.45% as of Jun 30, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 35.95%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 49.01%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.11%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -124.26%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 39.16%
10 Global Innovative Platforms 24.88 Mn 24.27 Mn - -453.17%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -453.17%
Mar 31, 2026 -129.79%
Dec 31, 2025 -148.05%
API Access

Global Innovative Platforms EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=GIPL&period=max&api_key=YOUR_API_KEY